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Abstract
Background: Autism spectrum disorders (ASD) are early onset neurodevelopmental syndromes typified by
impairments in reciprocal social interaction and communication, accompanied by restricted and repetitive
behaviors. While rare and especially de novo genetic variation are known to affect liability, whether common
genetic polymorphism plays a substantial role is an open question and the relative contribution of genes and
environment is contentious. It is probable that the relative contributions of rare and common variation, as well
as environment, differs between ASD families having only a single affected individual (simplex) versus multiplex
families who have two or more affected individuals.
Methods: By using quantitative genetics techniques and the contrast of ASD subjects to controls, we estimate
what portion of liability can be explained by additive genetic effects, known as narrow-sense heritability.
We evaluate relatives of ASD subjects using the same methods to evaluate the assumptions of the additive
model and partition families by simplex/multiplex status to determine how heritability changes with status.
Results: By analyzing common variation throughout the genome, we show that common genetic polymorphism
exerts substantial additive genetic effects on ASD liability and that simplex/multiplex family status has an impact on
the identified composition of that risk. As a fraction of the total variation in liability, the estimated narrow-sense
heritability exceeds 60% for ASD individuals from multiplex families and is approximately 40% for simplex families.
By analyzing parents, unaffected siblings and alleles not transmitted from parents to their affected children,
we conclude that the data for simplex ASD families follow the expectation for additive models closely. The data
from multiplex families deviate somewhat from an additive model, possibly due to parental assortative mating.
Conclusions: Our results, when viewed in the context of results from genome-wide association studies,
demonstrate that a myriad of common variants of very small effect impacts ASD liability.
Keywords: Narrow-sense heritability, Multiplex, Simplex, Quantitative genetics
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Beliefs about the genetic architecture of autism
spectrum disorders (ASD) have changed dramatically
over the past few decades. Early twin studies produced
heritability estimates approaching 90% [1,2] and, while
no specific risk loci were known at the time, it was
believed that liability was conferred by a handful of
genes of large effect. Later, data on the distribution of
ASD within families, together with results from linkage
analyses, were interpreted to mean that liability arose
from many genes [3]. Recent work has definitively
demonstrated the substantial contribution of de novo
variation [4-11]. Indeed multiple studies of rare single
nucleotide and copy number variants (CNVs) have sug-
gested that 15% or more of liability traces to de novo
mutation, effects that are genetic but not inherited [2].
Importantly, despite notable recent successes in gene
discovery efforts, key questions remain regarding the
overall nature and scale of the genetic contribution to
ASD liability. For example, the contribution of genetics
is still debated: a recent large-scale twin study [12] esti-
mated only 38% of liability was accounted for by additive
genetic effects, while common environmental factors
accounted for 55% of the variance; whereas most studies
of twins find much higher heritability, including studies
of phenotypes in the broader spectrum (see [13,14] for
review). Moreover, despite a near-consensus that com-
mon and transmitted variation must confer liability,
multiple genome-wide association studies have so far
not revealed replicable common polymorphisms [15]
associated with ASD, and studies of rare structural and
sequence mutations have largely failed to account for
the anticipated risk associated with transmitted variation
[6,7]. Finally, since the earliest CNV studies in ASD,
it has been postulated that the architecture of simplex
and multiplex autism would be strikingly different [4].
However not all studies have found marked disparities
in the rate of de novo mutation in simplex versus
multiplex families, and large effect de novo mutations
have been characterized in both multiplex and simplex
families [9,16].
Consequently, to gain insight into the broad questions
regarding the nature of the genetic factors underlying
ASD, we have estimated how much of the population
variability in liability can be traced to inherited variation,
specifically the narrow-sense heritability of ASD. Yang
et al. [17] proposed elegant methods in which the herit-
ability of liability can be estimated as a function of the
covariance between trait values, in this instance affection
status [18], and the genome wide genetics of the sub-
jects. This contrasts with the usual approach of esti-
mating heritability from the distribution of trait values
in pedigrees. In the present study, these methods are
applied to two ASD data sets, one from the Simons
Simplex Collection (SSC) [19] and the other from the
Autism Genome Project (AGP) [20]. Importantly the
analysis of these two cohorts allows for an estimate of
the heritability of ASD in simplex versus multiplex
families as well as an assessment of how well the data fit
predictions for an additive model of inheritance [21].
When all risk variation acts additively, for example, and
no other forces alter the covariance of relatives, the
liability for relatives of an affected individual consistently
halves for each degree of separation from the proband.
Therefore, we also evaluate heritability tracing to SSC
and AGP parents and SSC unaffected siblings, evaluat-
ing the empirical results against simulation-derived
expectations. Finally we use the same techniques to
ask what residual heritability is contained in what the
field calls pseudo-controls, which are genotypes formed
from the alleles that parents did not transmit to their
affected offspring.
Methods
ASD families
DNA samples from SSC and AGP family members
genotyped on the Illumina Infinium
® 1Mv3 (duo) micro-
array or the Illumina Infinium
® 1Mv1 microarray were
analyzed here. Specifically qualifying SSC samples were
genotyped on the Illumina Infinium
® 1Mv3 (duo) micro-
array (71.8%) while most AGP samples were genotyped
on the Illumina Infinium
® 1Mv1 microarray (98.7%).
Both arrays genotype roughly 1,000,000 single nucleotide
polymorphisms (SNPs) and the overlap between the
SNP sets is almost perfect.
The SSC sample [19] includes >2,000 genotyped fam-
ilies. However, our analyses targeted a homogeneous
subset of these data. First, we included only samples
genotyped on an Illumina 1M array; families had to be
‘quads’ consisting of an unaffected mother and father, an
affected proband and an unaffected sibling; and all mem-
bers of a quad had to have complete genotypes (>95%
completion rate). Only samples of European ancestry
were included. European ancestry for the SSC families
was determined using GemTools [22,23] for all available
SSC probands. To conduct the ancestry analysis we
selected 5,156 SNPs with at least 99.9% calls for geno-
types, had minor allele frequency MAF >0.05, and were
at least 0.5 Mb apart. Individuals were clustered into
nine ancestry groups based on four significant dimen-
sions of ancestry. The central five clusters, which held
a total of 1,686 families, were identified as being of
European descent. The ancestry cluster information
combined with complete genotype information yielded a
total of 965 SSC families for the analysis.
The AGP Stage 1 dataset [16,20] comprised 1,471
families, of which 1,141 were previously identified to
be of European ancestry [20]. European ancestry was
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SSC families (see Additional file 1: Figure S1).
Clinical evaluation
Probands for the SSC and AGP cohorts were diagnosed
in a similar manner (for diagnostic protocol for SSC, see
[19]; for AGP, see [16,20]). All SSC parents were
screened for Autism Spectrum Disorder by the Broad
Autism Phenotype Questionnaire [24] (self-report) and
the Social Reciprocity Scale - Adult Research Version
[25] (informant report). Moreover, family history evalu-
ation excluded first-, second-, or third-degree relatives
who met diagnostic criteria for ASD or intellectual dis-
ability. For AGP families 46.2% were known to be multi-
plex, another 38.2% were identified as simplex on the
basis of a family history indicating no known first- to
third-degree relatives with ASD, and the remaining 15.6%
were of unknown status. Note that most AGP parents
were not systematically evaluated for ASD, unlike those
from the SSC, and when AGP parents were systematically
evaluated, the results were not used to screen out affected
individuals and thus multiplex families. In addition, while
all available SSC family members were genotyped, only
parent-proband trios were genotyped for the AGP even
when additional siblings were available.
Control subjects
Controls derived from a convenience sample, specifically
1,663 individuals from HealthABC [26]. Control samples
were also genotyped on the Illumina Infinium
® 1Mv3
(duo) array, like most of the AGP data, providing excel-
lent comparability with the case dataset. Moreover, we
reasoned that ASD is sufficiently rare (approximately 1%
[27]) that screened and unscreened controls would yield
similar results.
Filtering
To make heritability estimates comparable, we filtered
all families and control subjects based on the follow-
ing criteria: all were of European descent as determ-
ined by genetically-estimated ancestry (Additional file 1:
Figure S1); genotypes for all family members met strin-
gent quality control (QC) criteria; and control samples
met identical QC criteria.
For the three data sets we first chose SNPs genotyped
on all platforms. Then ambiguous AT, TA, CG, and GC
SNPs were removed. A total of 813,960 SNP across the 22
autosomes and chromosome X were included for further
quality evaluation. At the level of individuals, we required
that genotyping completion rate be greater than 98%, that
there be no discrepancy regarding nominal and genotype-
inferred sex, and no individuals in different families
were closely related. At the level of individual SNPs, each
SNP must have a genotype completion rate > 98%, have
MAF > 0.01, and produce a P-value for Hardy-Weinberg
equilibrium > 0.005. Following these QC steps, data from
965 SSC quad families and 1,141 AGP families were ana-
lyzed using genotypes from 713,259 SNPs.
Statistical calculations and motivation
Estimating heritability as a case-control contrast
Heritability of ASD from probands versus controls was
estimated using GCTA software [28], which encodes
the theory laid out in [17,18]. Prevalence of ASD was
taken to be 1% [27]. For each of the analyses, Genetic
Relationship Matrices (GRM) were determined for each
of the 23 chromosomes using the –make-grm option
in GCTA [28]. These were then combined in an over-
all matrix, using the –mgrm option in GCTA. The first
10 principal components of ancestry were determined
using –pca in GCTA. These 10 PCA were then used as
covariates for estimating the heritability using –reml in
GCTA. A prevalence of 0.01 for autism spectrum dis-
orders was used to transform the heritability on the
observed scale to the heritability on the liability scale.
The logic of estimating heritability from unaffected
family members
Due to the screening of SSC samples, no SSC parents
would meet criteria for ASD. Given that is the case, what
is the justification for assigning them to be affected and
contrasting them to controls to estimate the heritability
in the parental generation? Under the additive heritabil-
ity model parents transmit many genetic variants of
small effect to their offspring, with the expectation that
half would be transmitted from each parent. The parents
of probands are thus more similar at liability loci than
expected by chance, and our goal is to estimate this
increased genetic similarity. Calling the parents affected
and contrasting their genotypes to that of controls is a
natural approach to estimating their genetic contribution
to liability and it has precedence in quantitative genetics,
such as estimation of the heritability of milk production
from its covariance arising from bulls, when only the
bull’s female progeny give milk (for example [29]).
A similar argument follows for unaffected siblings
from SSC families. These siblings should receive a ran-
dom sample of the parent’s genomes and, in expectation,
this sampling would include half the liability alleles car-
ried by each parent. Thus the unaffected offspring
should mirror the average liability carried by the parents
and this level can be estimated by calling them affected
and contrasting their genotypes to those from controls.
Simulations to compute expected heritability for parents
and pseudo-controls
While the literature contains numerous references to
the burden of risk variants carried by parents of simplex
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genetics analyses of it as a function of ascertainment
(there is related work on the impact of multi-locus
inheritance on the power of candidate gene association
studies [30,31]). We therefore evaluated the expected
heritability for parents, unaffected siblings, and pseudo-
controls on the basis of simulations and the theory of
quantitative genetics regarding the selection differential
(for ASD, approximately 1%) and the response to selec-
tion (expected change in the population’s mean liability).
The simulations are designed to mimic ascertainment
for simplex and multiplex families.
One thousand SNPs having an impact on liability
were simulated. The allele frequency for SNP i, pi, varied
between 0.01 and 0.99. Overall heritability h
2 across all
n = 1000 SNPs was set to be either 0.50 or 0.75 for
probands with ASD. The relative importance of each
SNP, wi, was determined by first selecting a fraction
ti between 0 and 1 at random using a uniform distri-
bution. These 1000 values were added to obtain T,
and each SNP was weighted by wi =t i/T. The allele sub-
stitution effect for each SNP i was then determined as
ai ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
wih2
i
2pi 1 pi ðÞ
q
. For each simulation 1000 families were
generated consisting of a father, mother, and one child
(AGP simplex) or two children (SSC simplex or AGP
multiplex). Genotypes for the parents were assigned at
random using the allele frequencies, while children
received alleles from the parents using the rules of
Mendelian inheritance. Likewise a pseudo-control was
generated by comparing the genotype of the parents
to that of the proband and assigning the un-transmitted
allele of each parent as the alleles for the pseudo-
control’s genotype. After all genotypes in a family were
assigned, the genetic contribution to the underlying
liability phenotype for each individual j in the family
was determined by Gj=
P
i=1
n xiai−μG in which xi is
the allele count for SNP i and μG =
P
i=1
n pi(1− pi)ai
is the average genetic contribution over all genotypes.
To simulate the environmental influence on the phe-
notype of individual j, ej, we drew a random number
from a normal distribution with mean 0 and variance
(1-h
2). The liability phenotype was then determined as
yj
u = Gj+ ej. Affection status was then assigned based on
affection status ¼
not affected when yu
i < 2:326
affected when yu
i ≥ 2:326
 
representing a disease risk of 1% in the population.
Four different scenarios were simulated:
1. Primary child in the family is affected (proband),
and father, mother, and designated sibling were
not-affected (SSC family);
2. Proband is affected, no restriction on the other
individuals in the family (unscreened simplex family);
3. Proband and second child are both affected, no
restriction on the other individuals in the family
(unscreened multiplex family);
4. A mixture of 60% unscreened simplex families and
40% unscreened multiplex families.
By using rejection sampling, a total of 1000 families
were generated for each scenario and this procedure was
repeated 100 times per scenario and proband heritability
(50 and 75%). To obtain the heritability estimates for the
family members, the average phenotype of the primary
probands on the liability scale (S) were compared to the
average phenotype of the family member of interest on
the liability scale (R). The heritability estimate based on
the family member was estimated as h
^2
¼ R
S. Note that
we also checked the heritability estimated from the pro-
bands as a function of the reduction in genetic variance
in the selected group. For probands, estimated heritabil-
ity was always close to 50% when that was the desired
heritability and always close to 75% when that was the
desired heritability.
From theoretical considerations we expected assorta-
tive mating to elevate the expected liability of pseudo-
controls and evaluated its impact by a simple experiment
using the simulation structure just described. Rather
than randomly assign genotypes to mates, we first
randomly chose the paternal genotypes at the 1,000
liability SNPs, then assigned maternal genotypes on the
basis of the toss of a fair coin: heads the genotype was
chosen at random, tails it was taken to be the father’s
genotype. All simulations procedures were as described
above, except we conducted two simulations: for sim-
ulation (a) the heritability of probands from simplex
families was taken to be 50% and ascertainment followed
scenario 2 above; and for simulation (b) the heritability
of probands from multiplex families was set to 75% and
ascertainment followed scenario 3 above.
Robustness of results
To evaluate the robustness of the results, 1,986 indivi-
duals of European descent from the Neurogenetics
Research Consortium [32] (NGRC) were available through
dbGap [33] and used as a second control sample. For
the NGRC study, genotypes were produced using the
Illumina Infinium
® Human Omni2.5 microarray. There-
fore, to combine all four data sets, we performed QC
on 444,200 SNPs genotyped on all platforms, yielding
391,425 SNPs for analyses.
Assessing the potential for experimental bias
To explore the impact of different cohorts and genotyp-
ing protocols on estimated heritability, we conducted a
series of contrasts between SSC and AGP samples of the
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fathers, and pseudo-controls – as well as HealthABC
versus NGRC controls.
Determining genomic coverage
While 713,259 SNPs were used for primary analyses,
they constitute a small fraction of the SNPs in the
human genome. Hence the heritability presented could
underestimate total heritability. On the other hand,
because genotypes of SNPs in close proximity tend to be
correlated due to linkage disequilibrium, it does not
follow that the coverage of the genome by the SNPs
used here estimate only a small fraction of the heritabil-
ity. To determine the shortfall in “genomic coverage”
and how it impacts estimates of heritability, we per-
formed an experiment using data from the 1,000
Genomes project [34], under the assumption that cover-
age of common variants in the 1,000 Genomes data
is perfect. Assessing all SNPs genotyped in our data,
as well as subsets thereof, we estimated heritability
of liability. Using the same subsets, but in 1,000 Gen-
omes subjects, we estimated levels of genomic coverage.
We can then relate estimated heritability to genomic
coverage to develop a functional relationship between
the two.
We performed the experiment assessing “genomic
coverage” as follows. We assumed genomic coverage of
SNPs with MAF > 0.1 would be essentially complete for
the 379 European samples analyzed by the 1,000
Genomes project. From these genomes we selected 50
1Mb regions in which at least 500 SNPs in the 1,000
Genomes samples had MAF > 0.10. Coverage of these
regions by the 713,259 SNPs was calculated as a func-
tion of the number of other SNPs with MAF > 0.1 that
were tagged by (correlated with) them; call the set of
M = 713,259 SNPs “tagSNP”. The tagging evaluation
was implemented using Hclust [35]. Forcing tagSNP to
be in the set of selected tag SNPs from the region,
Hclust evaluated how many more independent SNPs
N were required to cover the region when the min-
imum linkage disequilibrium [36] r
2 amongst tags could
be no less than X,w h e r eX = {0.5, 0.7, and 0.9}. Then,
for each value of X, M/(M+N) estimates the coverage.
Next we randomly sampled 50, 25 and 12.5% of the
713,259 SNPs (356,630, 178,315, and 89,158 SNPs
respectively) five times and each time estimated coverage
for these subsets.
Human subjects research statement
The research described here is in compliance with the
Helsinki Declaration, including appropriate informed
consent or assent [16,19,20,26,32,33].
Results and discussion
Estimates of heritability (h
2)
Heritability of SSC probands, measured against HealthABC
controls, was found to be 39.6% (Figure 1A, Table 1). SSC
mothers, fathers and siblings, when contrasted to controls,
yielded an estimated heritability approximately half that of
probands (Figure 1A, Table 1), consistent with expected
values from theoretical analyses of an additive model
(Figure 1A). We also generate a “pseudo-control” from the
alleles that parents did not transmit to their affected
offspring by using the program Plink [37]. When these
pseudo-controls were contrasted to the unrelated control
sample they produce estimates roughly one-quarter of
that identified in probands and close to the theoretical
expectation, zero (Figure 1A), demonstrating that the
probands received the majority of risk alleles carried
by parents.
When heritability is estimated using AGP probands
(Figure 1B, Table 1), the point estimates are larger than
those from SSC (h
2=55.2% versus 39.6%) although the
95% confidence intervals overlap. Moreover the decline
in heritability for AGP parents relative to probands is
30% (55% for probands, 37% for parents), instead of the
50% seen for SSC, and heritability estimated from
pseudo-controls is also higher (38%), consistent with
parental values (Figure 1B, Table 1). These results sug-
gest that AGP parents carry a greater load of additive
risk variants than SSC parents and thus are, on average,
closer to the threshold of being affected.
A major difference between the SSC and AGP samples
was the ascertainment and assessment process. SSC par-
ents were systematically screened on two instruments to
ensure they did not meet criteria for a spectrum diagno-
sis. Most parents from AGP families were not evaluated
in this way, and a small fraction of those parents met
criteria for ASD [9,16]. While not as systematic as the
SSC phenotyping assessment, most AGP families did
have available information about simplex versus multi-
plex status. Consequently, we were able to compare
heritability of probands from AGP multiplex versus sim-
plex families (Figure 1D, Table 2). The former was esti-
mated at 65.5% by comparison to HealthABC, whereas
probands for AGP simplex families it was 49.8%. Thus
estimates of heritability for AGP simplex probands
are somewhat closer to those from SSC probands
(Figure 1C) than to estimates for AGP multiplex pro-
bands. Moreover, for multiplex families and the mixed
set of AGP families (simplex/multiplex/unknown), both
the observed and expected heritability for first-degree
relatives was higher than that seen in simplex families
(Figure 1). These results comport with the literature
showing that unaffected relatives from multiplex families
tend to exhibit more features of the broader autism
phenotype than relatives in simplex families [38-40] (see
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simplex samples).
A curious observation from AGP multiplex families
was that fathers generate larger heritability than
mothers. We reasoned that this could be explained by
three plausible hypotheses: (1) the confidence intervals
of the paternal and maternal estimates overlap, so there
is no true difference; (2) the load of risk variants is, in
fact, greater for AGP fathers; or (3) fathers carry a larger
number of both liability and protective alleles. The last
of these requires some elaboration. Males are at much
greater risk for ASD than females (4:1 or greater) and
parents carry additive risk factors, yet AGP fathers and
mothers are largely unaffected. It is possible, then, that
the increased allele sharing in unaffected fathers is due
to a greater proportion of protective alleles, with females
being resilient for some other reason (for example,
estrogen/testosterone balance) in the face of a similar
degree of genetic risk.
Our results support either the first or second hypo-
theses but are not consistent with the third. The first
hypothesis is impossible to rule out given the limited
sample size. For the second hypothesis, if AGP fathers
were simply carrying greater risk, some of those
additional risk alleles would be carried by the pseudo-
controls and the heritability obtained from the contrast
of probands and pseudo-controls should be substantially
smaller than that observed from probands versus
controls. Indeed the values are substantially smaller:
10.9% vs. 39.6% for SSC; 14.5% vs. 55.2% for all
AGP; 0.0% vs. 49.8% for simplex AGP, and 27.1% vs.
65.5% for multiplex AGP. Finally, if (3) were true,
then contrasting probands to pseudo-controls would
produce substantial estimates of heritability because of
Table 1 Heritability estimates and their standard errors (se) based on contrasts to HealthABC controls using genotypes
from 713,259 SNPs
SSC AGP
Simplex All Simplex Multiplex
Estimate se Estimate se Estimate se Estimate se
Probands 0.396 0.082 0.552 0.068 0.498 0.118 0.655 0.139
Mothers 0.199 0.082 0.371 0.070 0.314 0.119 0.377 0.141
Fathers 0.196 0.084 0.370 0.070 0.352 0.119 0.666 0.143
Siblings 0.158 0.082 –– –– ––
Pseudo controls 0.090 0.082 0.381 0.070 0.317 0.120 0.503 0.146
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Figure 1 Estimated heritability for Autism Spectrum Disorders from ASD probands (Pr), as well as for their mothers (Mo), fathers (Fa),
siblings (Si) and pseudo-controls (Pc). Blue dotted reference line is set to the estimated heritability from probands; the black line marks the
expected heritability for first degree relatives; and the gray line marks the expected heritability from pseudo-controls. Expected values derived
from simulations mimicking the recruitment strategy producing the samples for (A)-(D). (A) Simons Simplex Collection or SSC data; (B) Autism
Genome Project or AGP data; (C) AGP data, only simplex families; (D) AGP data, only multiplex families.
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is not observed.
Distribution of liability alleles in the genome
If the additive variation for liability to ASD conforms
to the traditional polygenic or infinitesimal model, then
liability variants should be distributed at random over
the genome. The implication is that if heritability were
estimated for each chromosome, the resulting estimates
should be correlated with the lengths of the chromo-
somes. On the other hand, if the heritability traced to a
relatively small number of variants, even a few dozen,
such a correlation would be unlikely. In fact, we observe
significant correlation between per-chromosome herit-
ability and chromosome length (Figure 2), both for sim-
plex (r = 0.46, P value = 0.028) and multiplex (r= 0.54,
P value = 0.0075) families.
I nF i g u r e2t h ed e v i a t i o nf r o mp r e d i c t i o nf o rc h r o m o -
some X is surprising. For both multiplex and simplex
families, heritability estimated from X is less than that pre-
dicted by its size. This is noteworthy because chromosome
X has been cited as a possible source of sex-differential li-
ability for ASD [41]. Our results suggest that common var-
iants affecting liability do not cluster on chromosome X.
Evaluating robustness of results
To evaluate the robustness of our results, we first
contrasted the genotypes of SSC and AGP probands to
a second large set of controls, 1,986 individuals from
the Neurogenetics Research Consortium [32,33]. These
samples, genotyped on the Illumina Infinium
® Human
Omni2.5, were filtered and subjected to QC in an identi-
cal fashion to the HealthABC control set. There was ex-
cellent agreement of heritability estimates for ASD from
the two control samples (Tables 2 and 3) despite differ-
ences in ascertainment of the controls and the different
genotyping platforms.
Table 2 Heritability estimates and their standard errors (se) based on contrasts to HealthABC and NGRC controls using
genotypes from 391,425 SNPs
SSC AGP
HealthABC NGRC HealthABC NGRC
Estimate se Estimate se Estimate se Estimate se
Probands 0.395 0.082 0.378 0.073 0.553 0.068 0.586 0.063
Mothers 0.200 0.082 0.232 0.074 0.371 0.070 0.342 0.065
Fathers 0.196 0.084 0.153 0.073 0.373 0.070 0.518 0.063
Siblings 0.158 0.082 0.170 0.073 –– ––
Pseudo controls 0.090 0.082 0.107 0.073 0.380 0.070 0.446 0.065
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Figure 2 Estimated heritability per chromosome for simplex and muliplex families. In this figure chromosome X is marked distinctly,
but each chromosome is mapped by its length.
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platforms on estimates of heritability was explored by
conducting a series of contrasts between SSC and AGP
samples of the same relationship type: contrasting
probands, mothers, fathers, and pseudo-controls. Note
that most SSC samples were genotyped on the Illumina
®
1Mv3 (duo) microarray (71.8%) while most AGP
samples were genotyped on the Illumina Infinium
®
1Mv1 microarray (98.7%). Contrasts between SSC and
AGP samples of the same relationship type (Additional
file 3: Table S2) produce estimates close to the difference
between their control-based heritability. Indeed the
estimates from direct contrasts were usually smaller than
the difference of control-based heritability (for probands,
0.08 vs. 0.15 ≈ 0.552-0.396 from Table 1; for mothers,
0.11 vs. 0.17; for fathers, 0.19 vs. 0.17; and for pseudo-
controls, 0.22 vs. 0.29). Thus these results are not
consistent with effects attributable to genotyping plat-
form or ascertainment beyond multiplex/simplex status.
Implicit in these results is common genetic liability -
SSC and AGP probands must share many liability
variants despite their differences in ascertainment.
Indeed when AGP multiplex probands are contrasted to
SSC probands the resulting heritability is 0.23, quite
similar to that expected by the difference in their esti-
mated heritability (0.66 - 0.40 = 0.26); and when AGP
simplex probands are contrasted to SSC probands, the
resulting estimated heritability, 0.0, is below that of the dif-
ference in their estimated heritability (0.50 - 0.40 = 0.10).
These results suggest that the difference between multi-
plex and simplex families is largely a matter of degree (see
also [42]), namely the number of liability alleles carried by
parents, rather than a fundamental difference in the gen-
etic architecture [4,43].
Given the remarkable similarities of heritability esti-
mates obtained for either set of control samples (Tables 2
and 3), one might anticipate there would be little, if
any, difference between these controls. When we con-
trasted these control samples, however, they produced a
heritability of 26.5% (Additional file 3: Table S2). Math-
ematically, estimates of heritability arise from a high
dimensional space of allele frequencies, phenotypes and
their interrelationships. Therefore even if two controls
groups evoke similar estimates of ASD heritability from
the same sample of probands, the controls themselves
need not be close in the multidimensional space of allele
frequencies. What generates the differentiation between
controls is unknown. It could arise from the different
genotyping platforms or from differences in ascertain-
ment. In light of this difference, the fact that both con-
trols sets give rise to nearly identical estimates of
heritability for all proband subsets is remarkable and
suggests that the similarity amongst cases overwhelms
differences between the controls.
Heritability of pseudo-controls
There remains an unexplained feature of the results:
estimates of heritability for pseudo-controls tend to be
elevated over their theoretical values (Figure 1). Several
genetic forces could be at play. The simulations to derive
the distribution of liability in families also produce esti-
mates for pseudo-controls. Those results show (Figure 1)
that while the expected heritability for simplex families
is zero, multiplex status raises the expected value to
20%. It is not unreasonable to assume that the simplex
collections analyzed here contain families with unreal-
ized multiplex potential, and that might be especially
true for AGP families that had ascertainment criteria less
stringent than those for SSC families.
A factor that will elevate the expected heritability in
pseudo-controls is positive assortative mating (hence-
forth assortative mating). Assortative mating on pheno-
types related to ASD liability has been previously
reported [39]. When parents are genetically similar at
liability loci and they bear affected offspring, their
gametes will tend to be highly enriched for risk alleles,
even those that are not transmitted to affected offspring.
Simple simulations mimicking assortative mating show
that it can exert an impact similar to the difference be-
tween simplex and multiplex status. When simplex pro-
bands had heritability of 50% (that is, simulation a in
Methods), the expected heritability of pseudo-controls
Table 3 Heritability estimates and their standard errors (se) based on contrasts to HealthABC and NGRC controls using
genotypes from 391,425 SNPs but separating the AGP data into multiplex and simplex families for estimation
AGP multiplex AGP simplex
HealthABC NGRC HealthABC NGRC
Estimate se Estimate se Estimate se Estimate se
Probands 0.650 0.139 0.710 0.140 0.503 0.117 0.494 0.114
Mothers 0.369 0.141 0.387 0.136 0.311 0.119 0.268 0.117
Fathers 0.664 0.143 0.693 0.140 0.359 0.119 0.520 0.113
Pseudo controls 0.497 0.146 0.524 0.140 0.323 0.120 0.438 0.117
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When multiplex probands had heritability of 75%, the
expected heritability of pseudo-controls was 42.8% –
versus 20.2% without assortative mating. These simple
experiments were not intended to cover the range of
plausible scenarios for assortative mating relevant to
ASD, which would be impossible, but rather to demon-
strate the effect of such mating on the nature of pseudo-
controls. Thus assortative mating could be an important
and salient source of enrichment. Whether these forces
explain all of the elevated heritability for pseudo-
controls will require further data and analyses.
Impact of genome coverage
Because the set of SNPs used for primary analyses con-
stitute a small fraction of the SNPs in the human gen-
ome, estimates of heritability (Figure 1) could be biased
downward. Still, due to linkage disequilibrium, the
degree of bias is not trivial to estimate. Therefore
we performed an experiment to evaluate the shortfall
in genomic coverage and how it impacts estimates of
heritability. Results from the experiment are shown
in Additional file 4: Figure S2, in which estimated herit-
ability was plotted against estimated coverage. These
results suggest that heritability estimates from probands,
as shown in Figure 1, are good approximations. They
represent only slight underestimates of what would be
obtained had the entire genome been sampled.
In total our results demonstrate that a substantial
portion of ASD liability arises from inherited variation
acting additively. This pattern holds both for simplex
and multiplex families, with the burden of liability
greater in multiplex families, consistent with theoretical
and empirical [38-40] results. The modeling reported
here does not differentiate between additive effects due
to common versus rare variation. Nonetheless it is rea-
sonable to assume that most of the estimated heritability
traces to common variants because linkage disequilib-
rium between the common variants analyzed and rare
liability variants should, on average, be small [44]. Thus
the additive contribution of rare variants to ASD liability
is likely underestimated. Imperfect coverage must also
have an impact, but our analyses suggest its impact is
not large (Additional file 4: Figure S2).
Our analyses cannot address other features of the gen-
etic architecture of ASD, including non-additive genetic
effects, which add to ASD’s broad-sense heritability [45],
and de novo mutations. In addition, because they under-
estimate the impact of rare inherited variation, they dif-
fer from family-based estimates, such as from twin
studies, that do capture these effects. Still our findings of
substantial heritability are consistent with the majority
of twin studies [1,2] and are richer in some ways because
the analytic technique [17,18] used here provides a
direct estimate of the proportion of liability attribut-
able to additive genetic effects, whereas twin studies ob-
tain their estimates by relying on assumptions that are
approximations. For example, Zuk et al. [45] point out
that non-additive genetic effects are almost surely a
component of the genetic architecture of any trait, but
these effects cannot be captured by twin designs. Yet
for autism and other psychiatric disorders non-additive
genetic effects could be an integral component [46-48].
Twin designs also fail to capture other features,
such as maternal effects [49] and de novo mutations,
which are an important component of ASD genetic
architecture [4-11].
A recent ASD twin study [12] estimates 38% of ASD
liability traces to additive genetic effects while 55%
traces to common environment. Our point estimates
would be close to theirs if ascertainment of their families
was like that for SSC families, but not like that for AGP
families. A substantial fraction of their dizygotic twins,
however, are multiplex for ASD. Thus their point esti-
mate for heritability from additive genetic effects is low
relative to ours. If rare inherited variation contributes
substantially to liability for ASD, this makes the 38%
estimate seem lower still because twin studies should
capture these effects whereas our estimates cannot.
Genomewide association studies [18,50-52] have
detected only a handful of SNPs, all of small effect and
none replicating reliably. Teaming this observation with
our estimates of heritability (Figure 1) and the fact that
these studies are underpowered to detect genetic var-
iants of small effect size, but are otherwise well powered
[15], we conclude there must be thousands of SNPs scat-
tered across the genome with common liability alleles.
Analyses of chromosome-specific heritability support
this conclusion (Figure 2). Employing analyses like those
proposed by Stahl et al. [53] could estimate this distribu-
tion of effects.
Because these loci have small effect, samples far larger
than exist today will be required to identify a substantial
fraction of them using standard genome-wide asso-
ciation methodology. Hence, for the immediate future,
ample “missing heritability” for ASD will remain. Ingeni-
ous designs will be required in the near term [54]
to identify SNPs affecting liability. In the longer
term GWAS of a large number of ASD subjects, at
least on the order of that performed for schizophrenia
[55-57], should be one of the priorities for the field of
ASD genetics.
One way forward is to exploit shared liability across
psychiatric disorders, taking advantage of larger samples
[58] afforded by cross-disorder meta-analysis. There
is now sound evidence for common variants affecting
liability for schizophrenia [55-57], including a study
similar to ours [46]. Given the documented sharing of
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ample [59]), it would not be surprising to find that some
common variants affect liability to both schizophrenia
and ASD.
The estimated heritability for schizophrenia using
methods similar to ours is 23% [46]; for bipolar disorder
and similar methods it is 40% [60]; and for major de-
pression it is 32% [61]. None of these studies separate
out simplex and multiplex families, so in that sense
they are most comparable to the estimate obtained over
all AGP families, 55%, although the representation of
multiplex families in the AGP sample is likely larger
than for the other samples. Regardless of the differences
in simplex/multiplex representation, these estimates
are stochastically similar, in view of their standard
errors, emphasizing that common variants affect liability
for most if not all psychiatric disorders. Moreover their
impact appears to be similar in magnitude across dis-
orders, as measured by heritability estimated from
common variants.
That ASD shows the largest estimated heritability is
notable and could reflect the fact that the sibling recur-
rence risk is, on average, higher for siblings of an ASD
proband than for siblings of probands diagnosed with
schizophrenia, bipolar disorder or major depression. Sib-
ling recurrence risk is a ratio, defined as the probability
of a sibling being affected, given that the proband is
affected, divided by the prevalence of the disorder in the
general population. Recent studies put this recurrence
risk at almost 20 for ASD [62], whereas for schizophre-
nia it is 6 to 10 fold [63], for bipolar disorder it is 4 to 10
fold [64], and for major depression it is roughly twofold
[64]. The larger heritability could also trace to differences
among studies. It is possible that our estimates of herit-
ability are inflated by unknown differences between our
case and control samples, including ascertainment biases
and genotype quality. Regarding the latter, we selected
case and control samples genotyped on the same geno-
typing platform to minimize differences and we did not
detect any large differences in allele frequencies, but we
cannot rule out subtle differences in quality.
Regarding identification of common variants affecting
liability, our results suggest that the contrast of case and
pseudo-control genotypes, the “family-based” analysis, is
not optimal. In many samples pseudo-controls carry a
substantial burden of risk variants and their presence
degrades the power of family-based analysis to detect
risk SNPs (see also [30,31]). Instead it appears that
population-based controls contrasted with ASD cases
would be a more powerful design [65], even after
adjusting for ancestry [66]. In this regard it is intriguing
that the earliest GWAS of ASD [50] used population-
based controls to identify a single locus at 5p14.1, and
this result has since garnered support from a functional
study that reveals a plausible biological link to ASD
liability [67].
The genetic architecture of ASD has numerous compo-
nents: additive, non-additive and de novo genetic effects, as
well as gene-gene and gene-environment interactions. The
results shown here are relevant to only one of these compo-
nents. Other components, such as de novo events, are also
known to make a substantial contribution to liability [4-11],
w h i l eo t h e r sr e m a i nt ob et h o r o u g h l yi n v e s t i g a t e d[ 4 5 ] .
Already analyses of rare variation of major effect has
revealed a substantial number of genes affecting liability
[8-11,68-70]; it is reasonable to predict that common var-
iants regulating expression of those ASD genes could also
affect liability [71]. We hypothesize that the interplay of
rare and common variants is critical not only to liability it-
self, but to the expression of ASD or other relevant psychi-
atric and developmental disorders. The dynamics of this
interplay will likely be an important area for future autism
research.
Conclusions
Common genetic polymorphisms exert substantial additive
genetic effects on ASD liability and their impact differs by
ascertainment strategies used to recruit families. For sim-
plex families, who have only a single affected individual in
multiple generations, approximately 40% of liability traces
to additive effects whereas this narrow-sense heritability
exceeds 60% for ASD individuals from multiplex families.
Data for simplex ASD families follow the expectation for
additive models closely. Data from multiplex families
deviate somewhat from an additive model. This result is
consistent with what would bee x p e c t e df r o mp o s i t i v ea s -
sortative mating, but our data do not prove such a
pattern of mating occurred. In light of results from
g e n o m e - w i d ea s s o c i a t i o ns t u d i e s ,t h e r em u s tb em a n yc o m -
mon variants of very small effect affecting liability to ASD.
Availability of supporting data
The data sets supporting the results of this article
are available in the repositories: Simons Foundation
Autism Research Initiative, SFARI [http://sfari.org/sfari-
initiatives/simons-simplex-collection]; and the National
Institutes of Health database of Genotypes and Pheno-
types, dbGaP [http://www.ncbi.nlm.nih.gov/gap].
Additional files
Additional file 1: Figure S1. Ancestry projects for principal component
1 (PC.1) versus principal component 2 (PC.2) for the samples used in the
analysis of heritability. Red dots represent subjects with an ASD diagnosis
and blue are controls. HealthABC=HABC.
Additional file 2: Table S1. Heritability estimates and their standard
errors (se) using 391,425 SNP when AGP and SSC simplex family data are
combined or only multiplex AGP families are analyzed. Analyses include
all HealthABC and NGRC control samples.
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http://www.molecularautism.com/content/3/1/9Additional file 3: Table S2. Heritability estimates and their standard
errors (se) obtained when contrasting AGP and SSC samples of the same
relationship type, as well as contrasting HealthABC versus NGRC controls.
Additional file 4: Figure S2. Heritability for ASD probands as a function
of estimated “genomic coverage” for varying levels of r
2. Coverage is
estimated as the fraction of all known SNPs identified by 1000 Genomes
with minor allele frequency > 0.1 tagged by the set of SNPs used to
estimate heritability for probands; see Methods for more details. From
the left points map onto 12.5%, 25%, 50%, and 100% of the SNPs used to
estimate heritability. Top line is for probands from multiplex families,
bottom for probands from simplex families.
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